Dr Reddy’s Laboratories on Friday reported a consolidated web revenue of Rs 554 crore for the quarter ended March, down 28 per cent from Rs 764 crore in the identical interval of the earlier fiscal.
The corporate mentioned promoting, common and administrative (SG & A) bills went up by 17 per cent to Rs 1,430 crore as a consequence of incremental prices after the mixing of Wockhardt’s acquired divisions and elevated freight bills.
Consolidated revenues grew 7 per cent year-on-year to Rs 4,728 crore whereas R&D bills comprised 8.7 per cent of revenues at Rs 409 crore.
Earnings earlier than curiosity, taxes, depreciation and amortisation (EBITDA) have been up 13 per cent year-on-year throughout This autumn FY21 at Rs 1,133 crore.
For your entire yr (FY21), revenue after tax totalled Rs 1,915 crore on revenues of Rs 18,972 crore.
Co-Chairman and MD G V Prasad mentioned the corporate continued to develop throughout all companies, enhanced productiveness and strengthened growth pipeline.
“We’re prioritising our efforts to launch Sputnik V vaccine throughout India whereas engaged on the event and commercialisation of a number of medicine for the therapy of delicate to extreme Covid-19 infections.
(Solely the headline and movie of this report might have been reworked by the Enterprise Commonplace employees; the remainder of the content material is auto-generated from a syndicated feed.)